NDLI: Re-irradiation for recurrent glioma- the NCI experience in tumor control, OAR toxicity and proposal of a novel prognostic scoring system

Content Provider	Springer Nature : BioMed Central
Author	Krauze, Andra Valentina Peters, Cord Cheng, Jason Ning, Holly Mackey, Megan Rowe, Lindsay Cooley-Zgela, Theresa Smart, Dee Dee Camphausen, Kevin
Abstract	Purpose/objectives Despite mounting evidence for the use of re-irradiation (re-RT) in recurrent high grade glioma, optimal patient selection criteria for re-RT remain unknown. We present a novel scoring system based on radiobiology principles including target independent factors, the likelihood of target control, and the anticipated organ at risk (OAR) toxicity to allow for proper patient selection in the setting of recurrent glioma. Materials/methods Thirty one patients with recurrent glioma who received re-RT (2008–2016) at NCI – NIH were included in the analysis. A novel scoring system for overall survival (OS) and progression free survival (PFS) was designed to include:1) target independent factors (age, KPS (Karnofsky Performance Status), histology, presence of symptoms), 2) target control, and 3) OAR toxicity risk. Normal tissue complication probability (NTCP) calculations were performed using the Lyman model. Kaplan-Meier analysis was performed for overall survival (OS) and progression free survival (PFS) for comparison amongst variables. Results No patient, including those who received dose to OAR above the published tolerance dose, experienced any treatment related grade 3–5 toxicity with a median PFS and OS from re-RT of 4 months (0.5–103) and 6 months (0.7–103) respectively. Based on cumulative maximum doses the average NTCP was 25% (0–99%) for the chiasm, 21% (0–99%) for the right optic nerve, 6% (0–92%) for the left optic nerve, and 59% (0–100%) for the brainstem. The independent factor and target control scores were each statistically significant for OS and the combination of independent factors plus target control was also significant for both OS (p = 0.02) and PFS (p = 0.006). The anticipated toxicity risk score was not statistically significant. Conclusion Our scoring system may represent a novel approach to patient selection for re-RT in recurrent high grade glioma. Further validation in larger patient cohorts including compilation of doses to tumor and OAR may help refine this further for inclusion into clinical trials and general practice.
Related Links	https://ro-journal.biomedcentral.com/counter/pdf/10.1186/s13014-017-0930-9.pdf
Ending Page	10
Page Count	10
Starting Page	1
File Format	HTM / HTML
DOI	10.1186/s13014-017-0930-9
Journal	Radiation Oncology
Issue Number	1
Volume Number	12
Language	English
Publisher	BioMed Central
Publisher Date	2017-11-29
Access Restriction	Open
Subject Keyword	Cancer Research Oncology Radiotherapy Imaging Radiology Normal Tissue Complication Probability (NTCP) Left Optic Nerve Recurrent High-grade Glioma Optimal Patient Selection Criteria NTCP Calculations
Content Type	Text
Resource Type	Article
Subject	Radiology, Nuclear Medicine and Imaging Oncology
Journal Impact Factor	3.3/2023
5-Year Journal Impact Factor	3.6/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Re-irradiation alternatives for recurrent high-grade glioma.

Correction to expert consensus on re-irradiation for recurrent glioma

Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience

FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?

Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid)

Re-irradiation for high-grade gliomas: Has anything changed?

Validation of the prognostic Heidelberg re-irradiation score in an independent mono-institutional patient cohort

Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients

Re-irradiation of recurrent esophageal cancer after primary definitive radiotherapy.

Re-irradiation for recurrent glioma- the NCI experience in tumor control, OAR toxicity and proposal of a novel prognostic scoring system

Similar Documents

Re-irradiation alternatives for recurrent high-grade glioma.

Correction to expert consensus on re-irradiation for recurrent glioma

Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience

FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?

Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid)

Re-irradiation for high-grade gliomas: Has anything changed?

Validation of the prognostic Heidelberg re-irradiation score in an independent mono-institutional patient cohort

Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients

Re-irradiation of recurrent esophageal cancer after primary definitive radiotherapy.

Re-irradiation for recurrent glioma- the NCI experience in tumor control, OAR toxicity and proposal of a novel prognostic scoring system